AJP - Regu Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol (November 7, 2007). doi:10.1152/ajpregu.00466.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/1/R76    most recent
00466.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elmarakby, A. A.
Right arrow Articles by Pollock, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elmarakby, A. A.
Right arrow Articles by Pollock, D. M.
Submitted on July 2, 2007
Accepted on October 29, 2007

TNF-alpha inhibition reduces renal inflammation in DOCA-salt hypertensive rats

Ahmed A. Elmarakby1, Jeffrey E Quigley2, John D. Imig3, Jennifer S. Pollock2, and David M. Pollock4*

1 Pharmacology and Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, United States
2 Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, United States
3 Physiology, Medical College of Georgia, Vascular Biology Center, Augusta, Georgia, 30912-2500, United States
4 Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, United States; Physiology, Medical College of Georgia, Augusta, Georgia, United States

* To whom correspondence should be addressed. E-mail: dpollock{at}mcg.edu.

Studies suggest that the inflammatory cytokine, TNF{alpha}, plays a role in the prognosis of end-stage renal disease. We hypothesized that TNF{alpha} contributes to renal inflammation in a model of mineralocorticoid-induced hypertension. Four groups of rats (n=5-6) were studied for 3 weeks with the following treatments 1) placebo, 2) placebo + TNF{alpha} inhibitor, etanercept (1.25 mg/kg/day, sc), 3) deoxycorticosterone acetate plus 0.9 % NaCl to drink (DOCA-salt), or 4) DOCA-salt + etanercept. Mean arterial blood pressure (MAP) measured by telemetry increased in DOCA-salt rats compared to baseline (177±4 vs. 107±3 mmHg, P<0.05) and TNF{alpha} inhibition had no effect in the elevation of MAP in these rats (177±8 mmHg). Urinary protein excretion significantly increased in DOCA-salt rats compared to placebo (703±76 vs. 198±5 mg/day, respectively); etanercept lowered the proteinuria (514±64 mg/day, P<0.05 vs. DOCA-salt alone). Urinary albumin excretion followed a similar pattern in each group. Urinary MCP-1 and ET-1 excretion were also increased in DOCA-salt rats compared to placebo (MCP-1: 939±104 vs. 43±7 ng/day, and ET-1: 3.30±0.29 vs. 1.07±0.03 fmol/day, respectively, both P<0.05); TNF{alpha} inhibition significantly decreased both MCP-1 and ET-1 excretion (409±138 ng/day and 2.42±0.22 fmol/day, respectively, both P<0.05 vs. DOCA-salt alone). Renal cortical expression of ICAM-1, NFKB, TGF{beta}, and TNF{alpha} mRNA increased in DOCA-salt rats and etanercept reduced these changes. Renal cortical NFKB activity also increased in DOCA-salt hypertensive rats and etanercept treatment significantly reduced this effect. These data support the hypothesis that TNF{alpha} contributes to the increase in renal inflammation in DOCA-salt rats.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
N. G. Abraham, J. Cao, D. Sacerdoti, X. Li, and G. Drummond
Heme oxygenase: the key to renal function regulation
Am J Physiol Renal Physiol, November 1, 2009; 297(5): F1137 - F1152.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. Manhiani, J. E. Quigley, S. F. Knight, S. Tasoobshirazi, T. Moore, M. W. Brands, B. D. Hammock, and J. D. Imig
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension
Am J Physiol Renal Physiol, September 1, 2009; 297(3): F740 - F748.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. Misaki, T. Yamamoto, S. Suzuki, H. Fukasawa, A. Togawa, N. Ohashi, H. Suzuki, Y. Fujigaki, T. Oda, C. Uchida, et al.
Decrease in Tumor Necrosis Factor-{alpha} Receptor-Associated Death Domain Results from Ubiquitin-Dependent Degradation in Obstructive Renal Injury in Rats
Am. J. Pathol., July 1, 2009; 175(1): 74 - 83.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Venegas-Pont, J. C. Sartori-Valinotti, C. Maric, L. C. Racusen, P. H. Glover, G. R. McLemore Jr., A. V. Jones, J. F. Reckelhoff, and M. J. Ryan
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1282 - R1289.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. Shahid, J. Francis, and D. S. A. Majid
Tumor necrosis factor-{alpha} induces renal vasoconstriction as well as natriuresis in mice
Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1836 - F1844.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
B. LaMarca, J. Speed, L. Fournier, S. A. Babcock, H. Berry, K. Cockrell, and J. P. Granger
Hypertension in Response to Chronic Reductions in Uterine Perfusion in Pregnant Rats: Effect of Tumor Necrosis Factor-{alpha} Blockade
Hypertension, December 1, 2008; 52(6): 1161 - 1167.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.